100 ϫ 10 95% CI, 3.4-13.3) were associated with early-onset ARF, whereas injection drug use (OR, 4.8; 95% CI, 1.3-17.7), hepatitis C virus coinfection (OR, 3.4; 95% CI, 1.3-8.6), and nadir CD4 T cell count ! cells/L (OR, 5.8; 9 100 ϫ 10 95% CI, 2.5-13.4) were associated with late-onset ARF.
Conclusions. ARF was common and was associated with advanced immunodeficiency. The incidence of ARF decreased 110-fold in patients who had received HIV care for у3 months.
Acute renal failure (ARF) is defined as a rapid and usually reversible decrease in the glomerular filtration rate (GFR) in the context of previously normal renal function or in patients with preexisting chronic kidney disease [1] . Several reports have highlighted the susceptibility of HIV-infected patients to the development of ARF [2] . Before the availability of HAART, ARF was associated with younger age, advanced immunosuppression, volume depletion, septicemia, and opportunistic infections [3] [4] [5] . Acute tubular necrosis, hemolytic uremic syndrome, HIV-associated nephropathy, and drug-induced microtubular obstruction were common findings among patients with ARF in the pre-HAART era [3, 6] .
The epidemiology of ARF in HIV-infected patients in the HAART era has not been well defined. Two studies suggested that ARF remains an important complication of HIV infection [7, 8] , with an incidence of 5.9 episodes per 100 person-years among ambulatory patients [7] . ARF most often resulted from prerenal causes or acute tubular necrosis and was associated with advanced HIV infection (CD4 T cell count, !200 cells/ mL; HIV RNA level, 110,000 copies/mL; and AIDS), any HAART use, and hepatitis C virus (HCV) coinfection [7, 9] . Another study found that ARF was more common among HIV-infected, hospitalized patients in 2003 than in 1995 [8] . HIV infection remained a risk factor for ARF in the HAART era (OR, 2.82), and ARF is a risk factor for in-hospital mortality among HIVinfected patients (OR, 5.83) [8] . From these studies, it would appear that the availability of HAART has had little impact on the incidence of ARF. We studied the incidence of ARF during an 8-year period during the HAART era in a large, multiethnic cohort of HIV-infected outpatients. We used serum creatinine level and estimated GFR (eGFR) to assess renal function and to identify patients with ARF. We report the incidence of ARF over time since the initiation of HIV care, as well as clinical and laboratory parameters associated with ARF. 
METHODS

Case ascertainment.
As part of an ongoing study of kidney disease in HIV-infected patients, all HIV-infected patients aged у18 years who attended King's College Hospital, a large tertiary care hospital in southeast London, United Kingdom, during the period from January 1998 through December 2005 were identified. Serum creatinine values were obtained from the hospital's electronic patient record system and were converted into eGFRs, with use of age, sex, ethnicity, and the 4-variable modification of diet in renal disease equation [10] .
All patients with a nadir eGFR !60 mL/min during the study period were reviewed and were stratified as having chronic renal failure (CRF; defined as an eGFR !60 mL/min for 13 months) or not having CRF. In the absence of a universally accepted case definition, we used 3 eGFR-based criteria and 3 serum creatinine level-based criteria to define ARF in patients without CRF: (1) a confirmed eGFR of !60 mL/min, (2) a nadir eGFR 140% less than the baseline level, and (3) duration of renal failure (eGFR, !60 mL/min) of !3 months or (1) confirmed increase in the serum creatinine level (1120 mmol/L [1.36 mg/ dL]), (2) peak serum creatinine level 150% greater than the baseline level, and (3) duration of renal failure (defined as an increased serum creatinine level) of !3 months. Episodes of ARF identified by either set of criteria were included in the analysis. In addition, patients with CRF were determined to have "acute on chronic" renal failure if they experienced a confirmed 140% reduction in the eGFR in !3 months ( figure   1 ). Nineteen patients who developed ARF after admission to our hospital but who normally received HIV outpatient care elsewhere were excluded. The study was approved by the King's College Hospital Research Ethics Committee.
Data collection. The following demographic, clinical, and laboratory data were abstracted from the HIV clinical database: age, sex, ethnicity, risk factor for HIV acquisition, date of diagnosis of HIV infection, date of first and last attendance at the HIV service, presence of hypertension (defined as use of antihypertensive medication or presence of severe hypertension [systolic blood pressure, у141 mm Hg, and/or diastolic blood pressure, у91 mm Hg]), diabetes mellitus (defined as glucose intolerance requiring dietary or pharmacological interventions), AIDS-defining conditions and other comorbidities, hepatitis B surface antigen and hepatitis C antibody status, and nadir CD4 T cell count. Medical notes were reviewed for all patients who experienced ARF. Data on medical diagnoses, CD4 T cell counts, HIV-1 RNA levels, details regarding antiretroviral therapy, exposure to potentially nephrotoxic medications, the presence of reduced renal blood flow (due to dehydration, hypotension, and/or use of inotropes), liver disease, and use of respiratory or renal replacement support were recorded. In addition, microbiological and histological records for patients with ARF were reviewed. The association between decline in renal function and administration of potentially nephrotoxic medication was assessed for antimicrobial agents (i.e., acyclovir, amphotericin B, aminoglycosides, sulfadiazine, [high-dose] tri- methoprim-sulfamethoxazole, cidofovir, ganciclovir, indinavir, tenofovir, flucloxacillin, vancomycin, and rifampicin), cancer treatment, nonsteroidal anti-inflammatory drugs (NSAIDs), angiotensin-converting enzyme inhibitors, and acetominophen in toxic (over)dose.
Data analysis. Approximately 50% of all ARF episodes occurred within 3 months after initiation of HIV care (first HIV attendance at our hospital). Consequently, ARF episodes were classified as early onset (!3 months after initiation of HIV care) or late onset (у3 months after initial presentation). Baseline renal function was defined as mean eGFR and/or serum creatinine level prior to ARF or, in patients with impaired renal function at initial presentation, mean eGFR and/or serum creatinine level after ARF. The duration of ARF in patients without CRF was calculated as the number of days during which the eGFR was !60 mL/min.
We calculated the prevalence of ARF in the entire cohort and the incidence of ARF in patients who initiated care during the study period. The follow-up period was limited to the end of the study period (31 December 2005). Demographic, clinical, and laboratory parameters were compared for (1) patients with ARF and patients without renal failure (nadir eGFR, у60 mL/ min) and (2) those with early-onset ARF and late-onset ARF by use of the x 2 test, Fisher's exact test (for categorical variables), the Wilcoxon rank sum test, or Student's t tests (for continuous variables). Logistic regression was used to determine factors associated with early-and late-onset ARF. To reduce the risk of a type 1 error for multiple comparisons, we choose an a of 0.01. As a consequence, only differences between groups in the univariate analysis for which the P value was !.01 were considered to be statistically significant and were taken forward into multivariate analysis. Data were analyzed using Stata software, version 9.2 (Stata Corp.).
RESULTS
Prevalence and incidence of ARF.
During the period January 1998-December 2005, a total of 2274 patients received HIV care at King's College Hospital and were observed for 7394 person-years. Mean age at the study's inception was 34.6 years, 38% of subjects were female, 58% were black, and 6% had injection drug use as a risk factor for HIV acquisition. Overall, 1467 patients (67%) received HAART (which included indinavir or tenofovir for 119 and 475 patients, respectively) during the study period, and 1413 (69%) had у1 HIV RNA level measurement !400 copies/mL. The majority of patients (1752 [77%]) initiated HIV care during the study period, and of the 728 patients who presented with CD4 T cell counts !250 cells/ mm 3 , 658 (90%) initiated HAART after a median of 42 days (interquartile range, 14-95 days).
The nadir eGFR was у60 mL/min in 2043 (90%) of 2274 patients. CRF was present in 42 patients, 10 of whom experienced у1 episode of ARF. Of the 189 patients with nadir eGFR !60 mL/min and no CRF, 118 had cases that fulfilled the eGFR-based ARF case definition, and 116 had cases that fulfilled the serum creatinine-based ARF case definition. Altogether, 130 patients (5.7%) experienced 144 episodes of ARF (figure 1). Among the 1752 patients who initiated care after 1 January 1998, the incidence of ARF was 2.7 episodes per 100 person-years (95% CI, 2.3-3.2 episodes per 100 person-years). Because 73 (62%) of 118 ARF episodes occurred !3 months after initiation of HIV care, the incidence of early-onset ARF was 19.3 episodes per 100 person-years (95% CI, 15.4-24.1 episodes per 100 person-years), compared with 1.1 episodes per 100 person-years (95% CI, 0.83-1.49 episodes per 100 person-years) for late-onset ARF (rate ratio, 17.4; 95% CI, 12.0-25.2; ) (figure 2). Analysis by calendar year revealed a P ! .001 stable incidence of early-onset ARF among patients who initiated HIV care throughout the study period, as well as a trend toward a reduced incidence of late-onset ARF among patients receiving care.
Characteristics of patients who experienced ARF. Patients who experienced ARF more frequently had injection drug use as a risk factor for HIV acquisition, HCV coinfection, AIDS, and lower nadir CD4 T cells counts than did patients who did not experience renal failure (table 1) . When the characteristics of patients with early-onset and late-onset ARF were compared, important differences were noted. Patients who developed early-onset ARF were more likely to be black and to have acquired HIV infection through heterosexual transmission, whereas patients with late-onset ARF were more likely to be white, were more likely to have acquired HIV infection through injection drug use or sex between men, and were more frequently coinfected with HCV (table 1) . At the time of ARF diagnosis, patients with early-onset ARF had lower median CD4 T cell counts and were less likely to be receiving HAART, and few had attained viral suppression. Of the 73 patients with earlyonset ARF, 67 (91.7%) had newly diagnosed HIV infection, whereas HIV infection had been previously diagnosed in 6 patients (8.2%) who were not receiving care at the time of development of ARF. Duration and severity of renal failure were similar for patients with early-and late-onset ARF (table 2) . Etiology of ARF. The etiology of ARF in our patients was diverse and frequently multifactorial. Infections, malignancies, and liver disease were common in all patients with ARF and were accompanied by reduced renal blood flow in 70% of patients, use of NSAIDs in 27%, and administration of potentially nephrotoxic antimicrobial or antineoplastic agents in 67%. In 95% of patients with ARF, we identified у2 contributing etiological factors (e.g., infection, malignancy, drug toxicity, and/ or reduced renal blood flow).
AIDS-defining opportunistic infections were significantly less common among patients with late-onset ARF (table 2) . Mycobacteria, Toxoplasma gondii, Pneumocystis jirovecii, and Cryptococcus neoformans were the most common pathogens. In contrast, nonopportunistic infections (i.e., pneumonia, cellulitis, endocarditis, osteomyelitis, and "culture-negative" sepsis syndrome) were common among all patients with ARF, with Streptococcus pneumonia and Staphylococcus aureus being the most commonly identified pathogens.
Coinfection with hepatitis B virus and/or HCV was present in 47% and 41% of patients with liver disease (i.e., liver failure, alcoholic liver disease, flares of viral hepatitis, liver cancer, druginduced liver injury, and liver transplantation), respectively. Of the 20 HCV-coinfected patients, 7 had advanced liver cirrhosis at the time of ARF, as evidenced by thrombocytopenia, coagulopathy, and splenomegaly on ultrasound; 5 had infectious complications of injection drug use (i.e., endocarditis, osteomyelitis, or cellulitis); and 8 developed ARF that was unrelated to liver disease or injection drug use (i.e., ARF associated with pneumonia, opportunistic infection, diabetic ketoacidosis, or drug toxicity).
Malignancies were identified in 17% of ARF episodeschiefly cases of non-Hodgkin lymphoma (67%) and Kaposi sarcoma (17%)-whereas the toxic effects of antiretroviral therapy accounted for 14% of late-onset ARF episodes. The antiretroviral drugs involved included indinavir (nephrolithiasis; 6 cases), tenofovir (ARF without tubular dysfunction; 2 cases), and stavudine-didanosine (lactic acidosis; 2 cases). All episodes of antiretroviral-related toxicity were observed in patients with HIV RNA levels !400 copies/mL.
Seventeen patients with chronic kidney disease (10 of whom met the case definition of CRF) experienced 22 episodes of acute on chronic renal failure. The etiologies of CRF included HIV-associated nephropathy (8 episodes), other glomerulopathies (2 episodes), hypertension/vascular disease (4 episodes), hemolytic uremic syndrome (1 episode), drug toxicity (1 episode), and ureteric obstruction (4 ARF episodes in a single patient). ARF occurred within 90 days after commencement of HAART in 21 patients. In 6 patients, immune reconstitution inflammatory syndrome may have contributed to the development of ARF by unmasking opportunistic infections (due to Mycobacterium avium in 2 patients and P. jirovecii in 1 patient), worsening cryptococcal meningitis (in 2 patients), or inducing a hepatitis B flare (in 1 patient). In the other 15 patients, HAART was administered concurrently with potentially nephrotoxic cancer or antimicrobial chemotherapy to systemically ill patients without immune reconstitution inflammatory syndrome.
Factors associated with the development of ARF. The results of univariate and multivariate analyses of factors associated with early-onset and late-onset ARF are presented in table 3. In multivariate analyses, low nadir CD4 T cell count was strongly associated with both early-onset and late-onset ARF, whereas AIDS was associated with early-onset ARF, and injection drug use and HCV coinfection were associated with lateonset ARF.
DISCUSSION
Our results confirm that ARF remains a common complication of HIV infection in the HAART era. However, more than onehalf of all ARF episodes occurred within 3 months after initiation of HIV care, typically in patients with advanced HIV infection and opportunistic infections, other severe infections, or HIV-associated malignancies before HAART had been initiated. The incidence of ARF was 110-fold lower after the initial 3 months of HIV care, suggesting that HIV care (including receipt of HAART and chemoprophylaxis against opportunistic infections) is associated with a marked reduction in the risk of developing ARF.
Early-onset ARF generally occurred in patients with advanced immunodeficiency. A large proportion of "late pre- senters" in our cohort comprise patients who originate from sub-Saharan Africa, 5% of whom have active tuberculosis at the time of diagnosis of HIV infection [11] . Many of these patients were systemically ill and were given empirical treatment with broad-spectrum antimicrobials. Consequently, reduced renal blood flow and use of nephrotoxic medications were identified as factors contributing to the development of ARF in ∼70% of patients. Injection drug use and HCV coinfection, which are uncommon among patients from sub-Saharan Africa [12, 13] , were not associated with early-onset ARF. At our health care center, HAART is generally offered to all immunocompromised patients, in keeping with UK guidelines [14] ; it is typically started within 3 months after initial presentation. This was temporally associated with a reduction in the incidence of ARF-particularly ARF associated with opportunistic infections, the incidence of which was 70-fold reduced after the initial 3 months. In our patients, late-onset ARF was predominantly associated with clinical events for which the incidence is unaffected (or poorly affected) by HAART (e.g., nonopportunistic infections, liver disease, and sepsis related to active injection drug use) [15] . However, patients who were not receiving HAART or were not responding to HAART remain at risk of opportunistic infections, whereas those with satisfactory responses to HAART may still develop tuberculosis [16] or ARF, as a consequence of HAART toxicity [17, 18] ; immune reconstitution inflammatory syndrome [19] [20] [21] [22] ; or the unmasking of opportunistic infections [22] .
Previous studies have defined HCV coinfection as an important risk factor for developing ARF [7] [8] [9] , and our study confirms this association. However, we observed this association only in patients with late-onset ARF. Although approximately one-third of ARF episodes in HCV-coinfected patients occurred among those with clinically overt liver disease, onethird were associated with infectious complications of injection drug use, and one-third were probably unrelated to HCV coinfection and/or (prior) injection drug use. Optimal management of HCV coinfection and efforts to engage injection drug-using patients in care will be important strategies to reduce the incidence of ARF among HCV-coinfected patients.
HAART toxicity contributed significantly to late-onset ARF. Although !5% of our patients had been exposed to indinavir, this drug accounted for 50% of HAART-induced episodes ARF. Protease inhibitors with improved safety have replaced indinavir in our clinic, and all indinavir-related toxicity events were observed in the early part of the study period. Similarly, the use of thymidine-analogues and didanosine-sparing regimens as first-line antiretroviral treatment regimens has resulted in reduced incidence of lactic acidosis and pancreatitis, and these complications are now rarely observed. Despite its widespread use in our clinic (21% of all patients), tenofovir use was infrequent (5.4%) among patients with ARF and was considered a cofactor in the development of 2 ARF episodes (1.4%). Tenofovir-related toxicity affects a small proportion of patients and may present with various renal manifestations, including hypophosphatemia, Fanconi syndrome, ARF, CRF, hypokalemia, and nephrogenic diabetes insipidus [23] .
This study has several limitations. Although the use of eGFR is advocated as a measure of renal function in patients with chronic kidney disease, eGFR has not been validated as a means of defining ARF in HIV-infected patients, because the eGFR (as well as the serum creatinine level) may not accurately reflect glomerular function in patients with ARF. However, nadir eGFR and peak serum creatinine level provide a measure of the severity of renal dysfunction in patients with ARF, and serial values of either allow for estimation of the duration and degree of reversibility of kidney injury. The 2 previous studies of ARF in HIV-infected patients defined ARF as an increase in the serum creatinine level from !110 to 1180 mmol/L [3] or a graded increase in the serum creatinine level of at least 0.5 mg/ dL (44 mmol/L) for у2 days [7] . When applied to our 189 patients without CRF, the ARF definitions used by Peraldi et al. [3] and Franceschini et al. [7] identified 95 and 130 ARF episodes, respectively, of which 92 and 129 are included in this study. Although our criteria are likely to have identified most patients who experienced moderate-to-severe ARF during the study period, some episodes of mild ARF-or of moderately severe ARF in patients with extremely low muscle mass (and, thus, relatively low peak serum creatinine values)-may have been missed.
Our study is further limited by its retrospective nature. Cases of early renal failure may have been missed if HIV infection was suspected clinically but not confirmed serologically. Retrospective review made it difficult to be certain of the specific etiology of ARF. However, ARF is often multifactorial in etiology [1] , and we reported all identified contributing factors without speculating on their relative importance. Furthermore, patients who died or who were lost to follow-up may have developed ARF as a terminal out-of-hospital event, while attending another hospital in the United Kingdom, or after having left the United Kingdom. Finally, viral hepatitis status and information on diabetes and hypertension were missing for a large number of patients without renal failure, raising the potential for bias.
In summary, although ARF remains a common complication of HIV infection in the HAART era, patients are most vulnerable during the first 3 months after initiation of care. ARF is associated with advanced HIV infection and injection drug use and/or HCV coinfection. Efforts to reduce "late presentation" and initiation of HAART in patients with low CD4 T cell counts may reduce the risk of ARF. In hospitalized patients, dehydration and use of NSAIDs should be avoided, and nephrotoxic medications should used with caution, with close monitoring of renal function.
